Last $289.78 USD
Change Today -0.62 / -0.21%
Volume 3.2M
As of 4:15 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Open
$290.25
Previous Close
$290.40
Day High
$291.70
Day Low
$286.59
52 Week High
02/20/15 - $296.77
52 Week Low
04/14/14 - $184.71
Market Cap
81.0B
Average Volume 10 Days
4.2M
EPS TTM
$2.78
Shares Outstanding
279.4M
EX-Date
--
P/E TM
104.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Details

Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician’s offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreement with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. The company was founded in 1983 and is headquartered in Parsippany, New Jersey.

21,600 Employees
Last Reported Date: 02/18/15
Founded in 1983

actavis plc (ACT) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $2.6M
Chief Operating Officer
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

actavis plc (ACT) Key Developments

Actavis Receives Final Approval for Generic Version of Subutex

Actavis plc announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (Buprenorphine 2 mg and 8 mg sublingual tablets). Actavis intends to begin shipping its product shortly. Subutex is indicated for the treatment of opioid dependence. For the 12 months ending December 31, 2014, Subutex had total U.S. sales of approximately $108 million, according to IMS Health data.

Actavis plc Announces Consolidated Unaudited Earnings Results for Fourth Quarter and Year Ended December 31, 2014; Provides Standalone Earnings Guidance for the Year Ending December 31, 2015

Actavis plc announced consolidated unaudited earnings results for fourth quarter and year ended December 31, 2014. For the quarter, the company reported net revenues of $4,056.9 million, operating loss of $629.6 million, loss before income taxes and non-controlling interests of $794.9 million, net loss attributable to common shareholders of $732.9 million or $2.76 per diluted share compared to the net revenues of $2,779.3 million, operating loss of $74.6 million, loss before income taxes and non-controlling interests of $146.8 million, net loss attributable to common shareholders of $148.4 million or $0.86 per diluted share for the same quarter a year ago. Cash flow from operations for the fourth quarter of 2014 was $811.6 million against $651.7 million a year ago. Additions to property and equipment were $64.5 million against $60.5 million a year ago. Additions to product rights and other intangibles were $36.0 million against $125.0 million for the same period a year ago. Non-GAAP net income attributable to common shareholders was $1,050.6 million or $3.91 per diluted share compared to the $554.7 million or $3.17 per diluted share for the same quarter year ago. EBITDA was $265.8 million compared to $372.3 million a year ago. Adjusted EBITDA was $1,473.0 million compared to $817.1 million a year ago. Cash flow from operations was up 25% due to investment of $117 million in their generics business, $182 million in North American Brands business and $22 million in biosimilars. For the year, the company reported net revenues of $13,062.3 million, operating loss of $1,267.7 million, loss before income taxes and non-controlling interests of $1,712.1 million, net loss attributable to common shareholders of $1,630.5 million or $7.42 per diluted share, net cash provided by operating activities of $2,243.0 million, additions to property and equipment of $238.6 million, additions to product rights and other intangibles of $36.1 million compared to the net revenues of $8,677.6 million, operating loss of $423.2 million, loss before income taxes and non-controlling interests of $638.4 million, net loss attributable to common shareholders of $750.4 million or $5.27 per diluted share, net cash provided by operating activities of $1,213.5 million, additions to property and equipment of $177.9 million, additions to product rights and other intangibles of $130.0 million for the same period a year ago. Non-GAAP net income attributable to common shareholders was $3,112.7 million or $13.98 per diluted share compared to the $1,372.3 million or $9.50 per diluted share for the same period year ago. EBITDA was $1,518.9 million compared to $642.0 million a year ago. Adjusted EBITDA was $4,456.7 million compared to $2,244.4 million a year ago. Non-GAAP EPS was up 47% driven by net revenues, which increased by 48% to $12,846,000,000, which were again attributed to Forest's products that are reflected in third quarter and fourth quarter results. For the year 2015, the company expects GAAP net income attributable to ordinary shareholders will be in the range of $1,373.2 million to $1,644.4 million. Non-GAAP net income attributable to ordinary shareholders will be in the range of $4,405.5 million to $4,676.7 million. GAAP diluted earnings per share will be in the range of $5.08 to $6.08. Non-GAAP diluted earnings per share will be in the range of $16.30 to $17.30. Total net revenue is expected to be approximately $15 billion. Non-GAAP effective tax rate is expected to be approximately 16%.

Actavis Mulls Acquisitions

Actavis plc (NYSE:ACT) is looking for acquisitions. Actavis’ Chief Executive Officer, Brent Saunders, stated that the company will do acquisition if opportunity arises.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $289.78 USD -0.62

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.61 USD +0.21
AbbVie Inc $60.52 USD -0.10
Allergan Inc/United States $232.40 USD -0.08
AstraZeneca PLC 4,465 GBp -36.50
Eli Lilly & Co $70.03 USD -0.33
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.9x
Price/Book 2.7x
Price/Cash Flow 80.0x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.ie. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.